NCT03754244View on ClinicalTrials.gov

A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

TQB3456

Observe the safety and pk when the subjects take TQB3456 p.o. qd

Trial Locations (1)

200030

No. 241 Huaihai West Road, Xuhui District, Shanghai, Shanghai

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY